SAFETY AND EFFICACY OF MONOAMINE OXIDASE INHIBITORS IN THE TREATMENT OF ANXIETY DISORDERS: A SYSTEMATIC REVIEW AND META-ANALYSIS

荟萃分析 单胺氧化酶 焦虑 医学 药理学 心理学 精神科 内科学 生物 酶 生物化学
作者
Rafael C. R. Freire,Marcos Fidry,Clara Faria,Mariana Costa do Cabo,Ursula Medeiros Araujo de Matos,Ricardo Ewbank Steffen,Antônio Egídio Nardi
出处
期刊:The International Journal of Neuropsychopharmacology [University of Oxford]
卷期号:28 (Supplement_1): i267-i268 被引量:2
标识
DOI:10.1093/ijnp/pyae059.472
摘要

Abstract Background Monoamine oxidase inhibitors (MAOI) are well known for its effectiveness on major depressive disorder. MAOI’ s prescription has been declining since the arrival of new antidepressant drugs, and there are few studies on their efficacy and safety in the treatment of anxiety disorders. MAOI are controversial drugs because, in one hand, their efficacy is potentially superior to other antidepressants, due to their distinct mechanism of action. On the other hand, there are concerns about safety of these medications. Aims and Objectives The authors performed a systematic review and meta- analysis to investigate the efficacy and safety of MAOI. We also looked for evidence of superiority over other stablished drugs. Methods MEDLINE, PsycINFO, Web of Science, EMBASE, The Cochrane Library, Cochrane Central Register of Controlled Trials and ClinicalTrials.gov were searched for clinical trials using MAOI on anxiety disorders treatment, from January 1980 to May 2023. Review Manager 5 was used to analyze the effect size data, used as primary outcome. Results Over 2,972 records, 24 studies were included in the review. 19 studies were on social anxiety disorder treatment, 7 on panic disorder treatment. The studied MAOI were moclobemide, phenelzine, brofaromine and tranylcypromine. MAOI were superior to placebo in all 13 randomized controlled trials (RCT), except 2. MAOI were not superior to other antidepressants in comparative trials. They were effective on all 7 comparative trials and 4 open trials. 1,535 patients were pooled, only 6 (0.4%) showed severe adverse effects during trials. The risk of bias was high among the studies. Discussion and Conclusion MAOIs are effective treatments for social anxiety and panic disorders, although literature is scarce and there is high risk of bias. These medications demonstrated to be safe and effective. More clinical trials, with more stringent methodology are needed. References Lam RW, Kennedy SH, Grigoriadis S, McIntyre RS, Milev R, Ramasubbu R, Parikh S V, Patten SB, Ravindran A V. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. J Affect Disord. Netherlands; 2009 Oct;117 Suppl:S26-43. PMID: 19674794 Katzman MA, Bleau P, Blier P, Chokka P, Kjernisted K, Van Ameringen M, Antony MM, Bouchard S, Brunet A, Flament M, Rabheru K, Grigoriadis S, Richter PMA, Mendlowitz S, O’ Connor K, Robichaud M, Walker JR, Asmundson G, Klassen LJ, Lam RW, McIntyre RS, Szpindel I. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry. 2014. PMID: 25081580 Salzer HM, Lurie ML. Anxiety and depressive states treated with isonicotinyl hydrazide (isoniazid). Arch Neurol Psychiatry. 1953; Youdim MBH, Edmondson D, Tipton KF. The therapeutic potential of monoamine oxidase inhibitors. Nature Reviews Neuroscience. 2006. PMID: 16552415 Wimbiscus M, Kostenko O, Malone D. MAO inhibitors: Risks, benefits, and lore. Cleve Clin J Med. 2010; PMID: 21147941 ARNOT R. Calming effect of the monoamine oxidase inhibitors. Dis Nerv Syst. United States; 1960 Aug;21:448. PMID: 13794397Zisook S. A clinical overview of monoamine oxidase inhibitors. Psychosomatics. England; 1985 Mar;26(3):240-246,251. PMID: 3887453 Flockhart DA. Dietary restrictions and drug interactions with monoamine oxidase inhibitors: An update. Journal of Clinical Psychiatry. 2012. PMID: 22951238 Balon R, Mufti R, Arfken CL. A survey of prescribing practices for monoamine oxidase inhibitors. Psychiatr Serv. United States; 1999 Jul;50(7):945–947. PMID: 10402617 Fiedorowicz JG, Swartz KL. The role of monoamine oxidase inhibitors in current psychiatric practice. Journal of Psychiatric Practice. 2004.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
1秒前
1秒前
努力搬砖的小胡完成签到,获得积分10
2秒前
稳重的元瑶完成签到,获得积分10
2秒前
马亚斌完成签到,获得积分20
3秒前
瓦松完成签到,获得积分20
4秒前
等风归完成签到,获得积分10
4秒前
云朝完成签到,获得积分10
5秒前
6秒前
6秒前
ZeKaWa的应助被liu采纳,获得10
6秒前
PEACE完成签到 ,获得积分20
6秒前
儒雅黑猫完成签到 ,获得积分10
6秒前
7秒前
思恩Shen发布了新的文献求助10
7秒前
秦风完成签到,获得积分10
8秒前
杜欣悦发布了新的文献求助10
8秒前
香蕉觅云的应助被顺利毕业mpa采纳,获得10
8秒前
94完成签到,获得积分10
8秒前
fighting完成签到,获得积分10
9秒前
10秒前
10秒前
哈47发布了新的文献求助10
11秒前
俭朴含卉完成签到 ,获得积分10
11秒前
饼饼完成签到,获得积分20
11秒前
虚幻明杰完成签到,获得积分10
11秒前
Johnny发布了新的文献求助10
12秒前
wxz1998完成签到,获得积分10
12秒前
O基米德发布了新的文献求助10
12秒前
13秒前
田様的应助被木头采纳,获得10
13秒前
吱哦周完成签到,获得积分10
16秒前
17秒前
Diamond完成签到,获得积分10
17秒前
饼饼发布了新的文献求助10
17秒前
18秒前
秋风的应助被紧张的紫文采纳,获得10
19秒前
19秒前
思恩Shen完成签到,获得积分20
20秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181839
求助须知:如何正确求助?哪些是违规求助? 9571584
关于积分的说明 21818707
捐赠科研通 7778124
什么是DOI,文献DOI怎么找? 3433524
关于科研通互助平台的介绍 2557710
邀请新用户注册赠送积分活动 2479621